Nicholas M. Nagle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicholas M. Nagle has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Dale George Nagle
Shanghai Jiao Tong University, Shanghai, PR China
1 shared publication - Fakhri Mahdi
Division of Pharmacology, School of Pharmacy, University of Mississippi, Oxford, MS 38677, USA
1 shared publication - Mika B. Jekabsons
Department of Biology, College of Liberal Arts, University of Mississippi, Oxford, MS 38677-1848, USA
1 shared publication - Yu-Dong Zhou
Department of Ophthalmology, The First Affiliated Hospital, Zhejiang University School of Medicine, and Nanhu Brain-computer Interface Institute, Hangzhou, 310003, China; School of Brain Science and Brain Medicine, Zhejiang University, No.866 Yuhangtang Road, Xihu District, Hangzhou, 310058, Zhejiang, China
1 shared publication
Latest Publications
- Open Access
- 2 December 2025
- Published by MDPI AG in Marine Drugs
- Vol. 23 (12) , 464
Mechanistic Investigation of Adociaquinone and Xestoquinone Derivatives in Breast Cancer Cells
Xestoquinone derivatives isolated from marine sponges exhibit a range of bioactivities, including the inhibition of HIF signaling, mitochondrial function, and tumor cell proliferation. Mechanistic investigation suggested that 14-hydroxymethylxestoquinone (1) acts as a protonophore. Although adociaquinones A (5) and B (6) each stimulated cellular oxygen consumption, neither affected mitochondrial membrane potential. Cell-based respiration studies revealed that adociaquinones restored sodium azide-stalled oxygen consumption and ascorbate enhanced this response, suggesting ascorbate-supported redox cycling as a possible mechanism by which adociaquinones suppress HIF and tumor cell proliferation. These xestoquinone derivatives activated cellular stress response pathways that inhibit protein translation by phosphorylating key regulatory proteins (i.e., eIF2α, eIF4E, and eEF2). Further, thiol-reducing agents NAC and DTT attenuated the monosubstituted xestoquinone derivatives’ efficacy to inhibit HIF signaling, suggesting a potential mechanism of action that involves sulfhydryl modification.
- 2 December 2025
- Published by MDPI AG in Marine Drugs
- Vol. 23 (12) , 464
Open AccessMechanistic Investigation of Adociaquinone and Xestoquinone Derivatives in Breast Cancer Cells
Xestoquinone derivatives isolated from marine sponges exhibit a range of bioactivities, including the inhibition of HIF signaling, mitochondrial function, and tumor cell proliferation. Mechanistic investigation suggested that 14-hydroxymethylxestoquinone (1) acts as a protonophore. Although adociaquinones A (5) and B (6) each stimulated cellular oxygen consumption, neither affected mitochondrial membrane potential. Cell-based respiration studies revealed that adociaquinones restored sodium azide-stalled oxygen consumption and ascorbate enhanced this response, suggesting ascorbate-supported redox cycling as a possible mechanism by which adociaquinones suppress HIF and tumor cell proliferation. These xestoquinone derivatives activated cellular stress response pathways that inhibit protein translation by phosphorylating key regulatory proteins (i.e., eIF2α, eIF4E, and eEF2). Further, thiol-reducing agents NAC and DTT attenuated the monosubstituted xestoquinone derivatives’ efficacy to inhibit HIF signaling, suggesting a potential mechanism of action that involves sulfhydryl modification.